Findings from the COMPASS trial, aimed at establishing "the feasibility of a comprehensive real-time genomic analysis of pancreatic ductal adenocarcinoma (PDAC) using whole genome sequencing and RNA sequencing". While phenotypic profiling has been shown to be effective in treatment-based outcomes, a significant challenge is the 1.5-2 months of time required to receive whole genome sequencing results.
Click here to learn more.
Whole genome and RNA sequencing for pancreatic cancer is scientifically compelling, but a 1.5 to 2 month wait for results is a real clinical problem when the disease moves fast. Profiling only helps if the answer arrives while treatment decisions are still open. That implementation gap — between what the lab can do and what the clinic can use in time — comes up often in onc brothers conversations, especially for cancers where timing is everything.
ReplyDeleteThe COMPASS feasibility finding is the crucial first step — proving real-time whole genome and RNA sequencing can actually be done for PDAC is no small feat. But the 1.5 to 2 month wait for results in a disease that moves this fast is the brutal reality check. Profiling only changes outcomes if the answer arrives while treatment decisions are still open; that implementation gap is where the real work remains.
ReplyDelete